Shares of Pacira BioSciences (PCRX) have surged 66.8% in the past six months against the industry’s decline of 8.7%.  The stock has also outperformed the sector and the S&P 500 index during this timeframe.Strong quarterly results, consistent growth in sales of lead drug Exparel and encouraging pipeline progress have boosted investor sentiment.PCRX Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchExparel’s Performance Fuels PCRX GrowthExparel, Pacira’s flagship pain-management pro ...

Group 1 - The article discusses the challenges faced by Pacira BioSciences, Inc. (NASDAQ: PCRX) that have negatively impacted its share price [2] - The investment group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts, buy and sell ratings, product sales forecasts, and financial analyses [2] - The author, Edmund Ingham, has extensive experience in biotech consulting and has prepared detailed reports on over 1,000 companies in the sector [2] Group 2 - The article indicates that the author may initiate a long position in PCRX within the next 72 hours, suggesting potential interest in the stock [3] - There is a disclaimer stating that past performance does not guarantee future results, emphasizing the speculative nature of investments in the biotech sector [4]

-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders. Pacira issued the follo ...

Core Viewpoint - Pacira BioSciences has experienced a significant decline in stock price, down 76% over the last decade, while the S&P 500 has increased by 167% during the same period [2]. The management and board have compensated themselves nearly half a billion dollars, which is approximately 50% of the current market capitalization [2][3]. Management and Board Performance - Under the leadership of CEO Frank Lee, Pacira's stock price has decreased by 33% [1]. There are concerns regarding his push for higher compensation packages for management, which is seen as misaligned with shareholder interests [1][2]. Shareholder Interests - DOMA Perpetual Capital Management, which owns about 4.2% of Pacira's outstanding shares, argues that the current board's capital allocation strategy is detrimental to shareholder value [1][3]. DOMA emphasizes the need for a change in the board's composition to better align with shareholder interests and to rectify a decade of poor stock performance [1][2]. Director Nominees - DOMA has nominated three candidates for the board: Joseph Kromholz, Philip Pucciarelli, and Eric de Armas, who possess extensive experience in strategic capital allocation, risk management, and healthcare banking [1][6]. The nominees are expected to enhance the board's financial sophistication and legal expertise [1][2]. Capital Allocation Strategy - DOMA advocates for accelerating buybacks to return cash to shareholders and believes that the board should avoid substantial risks in capital allocation until there is certainty regarding ongoing intellectual property disputes [3]. The focus should be on prioritizing shareholder interests [3].

NEW YORK, March 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsu ...

Yes, the market has certainly seen its share of volatility recently. It’s led to some treacherous slides in equity prices. It seems that the high beta names are really getting slapped down. In most cases, the mega caps have stood in relatively well. Tuesday’s move to the 200-day on the S&P 500 brought out the bargain shoppers too. Many stocks managed to push into positive territory.On a bounce from those lows, resist the urge to buy everything that moves. Rather, look for stocks with strong earnings trends ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Pacira BioSciences, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Pacira securities is from August 2, 2023, to August 8, 2024, and the lead plaintiff deadline is March 14, 2025 [1]. - Investors can join the class action without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Allegations - The lawsuit alleges that statements made by Pacira during the Class Period were misleading, particularly regarding the patent protections on Exparel, which were critical for the company's growth [4]. - It is claimed that Pacira misrepresented the strength of its patent protections, knowing that the '495 patent was not as robust as publicly stated [4]. - The lawsuit asserts that when the true nature of the patent protections became known, investors suffered damages [4].

NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=132953&from=4 CLASS PERIOD: Augu ...

Core Insights - Pacira BioSciences reported fourth-quarter 2024 adjusted earnings of 91 cents per share, exceeding the Zacks Consensus Estimate of 86 cents and up from 89 cents in the same quarter last year [1][2] - Total revenues for the fourth quarter reached $187.3 million, a 3% increase year over year, but slightly missed the Zacks Consensus Estimate by 0.03% [2][10] Revenue Breakdown - The company's revenue primarily comes from product sales, specifically from its three marketed drugs: Exparel, Zilretta, and iovera. No royalty revenues were recognized in the fourth quarter [3] - Exparel's net product sales were $147.7 million, a 3% increase from the previous year, surpassing the Zacks Consensus Estimate of $145.3 million [4] - Zilretta's net product sales reached $33.1 million, up 15% year over year, exceeding the Zacks Consensus Estimate of $30.7 million [6] - iovera's net product sales were $6.5 million, a 7% increase from the year-ago quarter, slightly beating the Zacks Consensus Estimate of $6.4 million [7] Expense Analysis - Research and development (R&D) expenses (excluding stock-based compensation) were $22 million, a 33% increase from the previous year due to higher product development and clinical study costs [8] - Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) totaled $70.6 million, a 23% increase year over year, driven by investments in commercial and market access organizations [9] Financial Performance - For the full year 2024, Pacira recorded total revenues of $701 million, a 4% increase from 2023, but slightly below the Zacks Consensus Estimate of $701.9 million [10] - Adjusted earnings for 2024 were $3.20 per share, matching the Zacks Consensus Estimate and up from $2.81 in 2023 [10] Future Guidance - For 2025, Pacira expects total revenues to be in the range of $725-$765 million, with an adjusted gross margin projected between 76% and 78% [11] - Adjusted R&D expenses are anticipated to be between $90 million and $105 million, while adjusted SG&A expenses are expected to range from $290 million to $320 million [11] Recent Developments - The FDA approved a new Smart Tip for the iovera system to manage chronic low back pain, and Pacira secured a patent protecting Exparel's chemical composition until 2044 [12] - New phase I data for PCRX-201 showed improvement in knee pain and function for at least two years, with a favorable safety profile [13]

Financial Data and Key Metrics Changes - The company reported record revenues of $701 million for 2024, at the high end of the guided range [7] - Non-GAAP gross margin for Q4 was 79%, driven by improved margins for EXPAREL and ZILRETTA [46] - Adjusted EBITDA for the quarter was $62.5 million, indicating strong operational performance [46] Business Line Data and Key Metrics Changes - EXPAREL sales increased to $147.7 million in Q4 2024 from $143.9 million in Q4 2023 [45] - ZILRETTA sales rose to $33.1 million in Q4 2024 compared to $28.7 million in Q4 2023 [45] - Iovera sales were $6.5 million in Q4 2024, up from $6.0 million in Q4 2023 [45] Market Data and Key Metrics Changes - The NOPAIN Act now provides a reimbursement pathway for 18 million outpatient surgical procedures, with 6 million under CMS coverage and 12 million under commercial coverage [13] - The company has seen commercial payers adopting NOPAIN-like policies, doubling the previous commercial coverage map to approximately 40 million covered lives [17][18] Company Strategy and Development Direction - The company is focused on executing its 5/30 strategy, aiming for double-digit CAGR in product revenues over the next five years and expanding its innovative pipeline [9][11] - The acquisition of GQ Bio aligns with the 5/30 strategy, adding a high-capacity local delivery platform for genetic medicines [30][31] - The company plans to establish at least five clinical or commercial partnerships by 2030 to enhance its market presence [41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early signs of progress with the NOPAIN initiative, although they acknowledged that customer adoption will take time [62][63] - The company anticipates a more meaningful uptick in utilization and reimbursement in the second half of 2025 [51][80] - Management emphasized a disciplined approach to capital allocation, balancing growth investments with shareholder returns [49][74] Other Important Information - The company exited Q4 2024 with $485 million in cash and investments, positioning it well for future growth [47] - The board has undergone significant refreshment, reducing the average tenure of directors to less than five years [43] Q&A Session Summary Question: Can you discuss the assumptions for NOPAIN and the potential impediments to rapid uptake? - Management indicated that it will take time for customers to gain traction with NOPAIN, with early signs of progress being encouraging [62][63] Question: Are you seeing successful reimbursement and penetration into new accounts? - Management noted that while it is early days, they are seeing good traction and some commercial payer wins [66][68] Question: What is the company's approach to capital allocation given the growth potential? - Management emphasized a disciplined approach to capital allocation, focusing on funding current operations and innovation while managing the balance sheet [74] Question: Can you provide insight into the relative contributions of the product portfolio for 2025? - Management expects EXPAREL to remain the flagship product, with plans to support ZILRETTA and iovera as well [78] Question: What are the implications of the competitive landscape for the 5/30 growth strategy? - Management expressed confidence that there will not be a risk of generic launches in the near future, supporting their growth projections [82]